Platelet aggregation is currently felt to play an important role in the pathogenesis of ischemic vascular disorders. The smooth muscle relaxant, nitroglycerin, has been shown to inhibit platelet aggregation in vitro, but at concentrations that were felt to be unattainable in vivo. Because the in vivo action of nitroglycerin on smooth muscle cells has been shown to depend on the presence of reduced cytosolic sulfhydryl groups, the inhibitory effect of nitroglycerin on platelet aggregation was examined in the presence of the reduced thiol, N-acetylcysteine. Millimolar concentrations of N-acetylcysteine potentiated markedly the inhibitory effect of nitroglycerin on platelet aggregation induced by ADP, epinephrine, collagen, and arachidonate, decreasing the 50% inhibitory concentration (IC5,) -50-fold for each of these agents. Other guanylate cyclase activators inhibited ADP-induced aggregation similarly and this inhibition was likewise potentiated by N-acetylcysteine. Platelet guanosine 3Y5'-cyclic monophosphate content increased fivefold in the presence of nitroglycerin and N-acetylcysteine 2 min before maximal inhibition of ADP-induced aggregation was achieved, while simultaneously measured cyclic AMP did not change relative to base-line levels. In the absence of Nacetylcysteine, nitroglycerin induced a marked decrease in platelet-reduced glutathione content as S-nitroso-thiol adducts were produced. The synthetic S-nitroso-thiol, S-nitroso-Nacetylcysteine, markedly inhibited platelet aggregation with an IC5o of 6 nM. These data show that N-acetylcysteine markedly potentiates the inhibition of platelet aggregation by nitroglycerin and likely does so by inducing the formation of ad S-nitrosothiol adduct(s), which activate guanylate cyclase.
Introduction
The importance of platelets in the pathogenesis of myocardial ischemia and infarction has recently been recognized. Circulating platelet aggregates are more prevalent in patients with sudden coronary death than in patients who die of other causes (1, 2) . Vasoactive substances released by platelets at sites of endovascular injury, such as thromboxane A2 and lipoxygenase products, produce coronary vasospasm (3) (4) (5) . Furthermore, upon platelet activation, the platelet membrane itself serves as a catalytic surface on which coagulation factors interact in the formation of fibrin (6) , the presence of which further limits vessel patency.
Organic nitrate vasodilators, particularly nitroglycerin, have been used for many years in the treatment of ischemic heart disease (7) . The mechanism of action of these agents remains incompletely defined (8, 9) , but very likely involves direct smooth muscle relaxation in conductive (coronary) arteries (10, 11) . Given the role of the platelet in the pathophysiology of coronary ischemia, several groups have investigated the effect of organic nitrate vasodilators on in vitro platelet function (12) (13) (14) . Agonist-induced aggregation was uniformly inhibited by nitrates in these early studies, but the concentration of nitrates required was quite high and not achievable pharmacologically, thus calling into question the therapeutic relevance of this observation.
The work of Needleman et al. (15) demonstrated that the vasodilator action of nitroglycerin depends critically on the availability of certain essential sulfhydryl groups in vascular smooth muscle cells. These in vitro observations were extended in vivo by Horowitz et al. (16) , who showed that pretreating patients with the sulfhydryl agent, N-acetylcysteine, reduced the amount of nitroglycerin required to achieve a targeted reduction in mean arterial and mean pulmonary capillary wedge pressures.
Because of the importance of platelets in the pathogenesis of myocardial ischemia, the ability of organic nitrates to inhibit platelet function in vitro (albeit at excessive concentrations), and the potentiating effect of sulfhydryl agents on nitroglycerin action in smooth muscle cells, we investigated the effect of N-acetylcysteine on the inhibition of platelet aggregation by nitroglycerin and other organic nitrates. The data presented show the following: (a) that N-acetylcysteine markedly potentiates the inhibitory action of nitroglycerin on platelet aggregation in vitro to a variety of agonists; (b) that nitroglycerin (as other nitrate vasodilators) inhibit platelet aggregation by increasing intracellular cyclic GMP (cGMP) and N-acetylcysteine markedly potentiates this effect; (c) that nitroglycerin inhibits platelet aggregation through the formation of S-nitrosothiols, these latter compounds being both potent Cyclic nucleotide assays. Measurements of cGMP and cAMP were performed by radioimmunoassay. After incubating PRP at 370C with nitroglycerin and/or N-acetylcysteine, the platelets were processed as described previously (14) and radioimmunoassays for cGMP and cAMP performed. Acetylation of samples with acetic anhydride was used to increase the sensitivity of the assays.
Platelet glutathione measurements. GSH was measured in platelets by the method of Beutler et al. (18), with slight modifications. At various times after incubation with nitroglycerin, PRP was treated with 1.67% glacial metaphosphoric acid, 0.02% disodium (ethylenedinitrilo)tetraacetate, and 3% NaCi. The mixture was centrifuged at 8,700 g for 4 min at 4VC and the supernatant neutralized with 1.0 M Na2HPO4. DTNB was used to detect free sulfhydryl groups spectrophotometrically (19, 20) , using a molar extinction coefficient of 14,200 M-'cm-' for the nitrothiophenolate ion (21).
Nitrite determination. Free nitrite was assayed in the supernatant of trichloroacetic acid extracts of platelets incubated with nitroglycerin with or without N-acetylcysteine by the method of Snell and Snell (22) , which involved diazotization of sulfanilic acid and subsequent coupling with the chromophore N4--naphthyl)ethylenediamine. SNitroso-thiols were detected by assaying free nitrite by diazotization of sulfanilic acid in the presence and absence of 0.15% HgC12, the latter reagent catalyzing the hydrolysis of S-nitroso bonds (23).
Preparation ofS-nitroso-N-acetylcysteine. S-Nitroso-N-acetylcysteine was prepared at 250C by reacting equimolar concentrations of Nacetylcysteine with NaNO2 at acidic pH (24, 25) . Solutions turned from clear to rose-colored upon completion of the reaction. The Snitroso-thiol was identified by visible absorption spectroscopy, having an absorption maximum of 550 nm. The completeness of the reaction was verified by measuring free nitrite in the presence and absence of 0.15% HgCI2, as described in the above paragraph, and by measuring reduced sulfhydryl groups using DTNB. Due to the instability of the S-nitroso-derivatives, S-nitroso-N-acetylcysteine was prepared within 1 h of use, kept in acidic solution at 4VC, and diluted as necessary into aqueous buffer immediately before addition to assay systems.
Results
Inhibition ofplatelet aggregation by nitroglycerin. Nitroglycerin inhibited platelet aggregation induced by 11 MJM ADP in a typical dose-response fashion (Fig. 1) . The IC50 for this inhibition was 42 MM. Other agonists, including 12.5 AM epinephrine, 0.12 mg/ml calf skin collagen, and 0.44 mM arachidonate, were also inhibited with similar IC50s (Table I) . For each agonist, the extent of aggregation at any concentration of nitroglycerin was normalized to that in the absence of nitroglycerin and N-acetylcysteine.
Potentiation of the inhibitory effect of nitroglycerin by Nacetykcysteine. N-Acetylcysteine at 5.5 mM added to PRP 4 min before the addition of nitroglycerin (and 5 min before the addition of agonist) markedly potentiated the inhibitory action of nitroglycerin for each agonist tested ( Fig. 1 and Table I ).
The IC5o shifted from -42 to 0.71 AM for ADP with similar shifts noted for collagen, epinephrine, and arachidonate (Table  I) . At the concentration used in these experiments, N-acetylcysteine alone did not inhibit platelet aggregation; however, at higher concentrations, inhibition of aggregation by N-acetylcysteine alone was apparent. Lower concentrations of Nacetylcysteine also potentiated inhibition by nitroglycerin, the effect decreasing with decreasing concentrations of N-acetylcysteine.
Inhibitory effect of other guanylate cyclase activators on (27) showed that sodium nitroprusside and nitric oxide inhibited ADP-induced platelet aggregation and that this inhibition was preceded by an early, large, and partly transient increase in intracellular cGMP. For this reason, the effect of nitroglycerin on platelet cGMP was assessed and the influence of N-acetylcysteine on this effect examined. Total platelet cGMP was measured by radioimmunoassay in quiescent platelets and platelets incubated with nitroglycerin with and without N-acetylcysteine. Platelets in PRP were incubated with various concentrations of nitroglycerin with or without 5.5 mM N-acetylcysteine for 5 min at 370C, after which the platelets were processed as described previously (14) and cGMP determined. The incubation time used in this experiment was chosen because inhibition by nitroglycerin of platelet aggregation in the presence of N-acetylcysteine is maximal by 4 min and because subsequent experiments evaluating the time course of changes in platelet aggregation were carried out for as long as 5 min after addition of reactants (see below). As had been shown previously for nitroglycerin (14) , no change in platelet cAMP from basal levels of 3.5±0.5 pmol/108 platelets occurred in these experiments.
Time course ofincrease in platelet cGMP and inhibition of platelet aggregation. The temporal relationship between the increase in platelet cGMP and the decrease in ADP-induced platelet aggregation is shown in Fig. 2 . Platelets in PRP were incubated at 370C with 39 MM nitroglycerin for 1 min and 5.5 mM N-acetylcysteine was added at time zero. The incubation mixture was sampled at frequent times after addition of N-acetylcysteine to determine the maximal rate of platelet aggregation in response to 11 MM ADP, a value that typically was derived from no more than the first 15 s of the aggregation tracing after addition of ADP. (Please note: the extent of aggregation was not measured in these experiments because the time required to achieve the maximal extent of aggregation was prohibitively lengthy [up to 2 min] relative to the time course of changes in cGMP that were being simultaneously measured.)
The concentration of nitroglycerin used (39 WM) was chosen to permit measurement of aggregation rates that were less than completely inhibited, thereby permitting assessment of changes in rates at early times. Since the earliest time point sampled after addition of nitroglycerin was 1 min, the large and transient increase in cGMP described by Mellion et al. (27) (i.e., beyond 1 min) elevations of cGMP were measured in this experiment in order that they might be correlated better with changes in aggregation rate. Fig. 2 shows that by 30 s after addition of 5.5 mM Nacetylcysteine to platelets incubated with 39 !M nitroglycerin, cGMP levels increased fourfold to 0.90 pmol/108 platelets. Maximal inhibition of platelet aggregation rate (plotted with a reversed ordinate for purposes of comparison with the cGMP plot) lagged behind and was not attained until 2.5 min after addition of N-acetylcysteine. Thus, this experiment demonstrates that the increase in platelet cGMP induced by nitroglycerin in the presence of N-acetylcysteine preceded the attainment of maximal inhibition of platelet aggregation.
Effect ofnitroglycerin on reduced glutathione concentration in platelets. Nitroglycerin undergoes denitrification in smooth muscle cells and hepatocytes through the action of an organic nitrate reductase (28) . This denitrification requires GSH, the thiol undergoing oxidation in the process. GSH levels were measured in the quiescent platelet and found to be 4.0 X l0-'7 mol GSH/platelet, a value comparing favorably with published values (29) . Incubating platelets with increasing concentrations of nitroglycerin led to a reduction in this intracellular GSH to <10% of the base-line levels at -1 M nitroglycerin (Fig. 3). 6 t 3 _-. Effect ofS-nitroso-N-acetylcysteine on platelet aggregation.
S-nitroso-N-acetylcysteine, synthesized from N-acetylcysteine and NaNO2 as described in Methods, markedly inhibited platelet aggregation in response to 11 M ADP, as depicted in Fig. 4 . Incubating PRP for 5 min with S-nitroso-N-acetylcysteine inhibited aggregation with an IC50 of 6 nM; it is important to note that at equivalent concentrations of N-acetylcysteine or NaNO2 alone, no significant inhibition was noted ( Fig. 1 and Table II) , which supports the hypothesis that the adduct itself (and/or a metabolic product thereof) was the active species. Similar effects of S-nitroso-N-acetylcysteine were noted when using epinephrine (12.5 MM) and calf skin collagen (0.12 mg/ ml) as agonists (Table IV) . Formation of S-nitroso-thiols by platelets on incubation with nitroglycerin. Platelets in PRP were incubated with 2.2 mM nitroglycerin with or without 5.5 mM N-acetylcysteine for 5 min at 370C and extracted with TCA. The concentration of total nonprotein S-nitroso-thiol was determined by assaying free nitrite using diazotization and aromatic derivatization in the presence and absence of HgCl2 as described in Methods. Mercuric ions catalyze the hydrolysis of the nitroso moiety from the nitroso-thiol adducts and, in so doing, permit the determination of nitroso-thiols. In the absence of Nacetylcysteine, 1.5±0.5 nmol/108 platelets of S-nitroso-thiol was detected, while with N-acetylcysteine, this value increased to 5.1 ± 1.0 nmol/108 platelets. No nitroso-thiol was detected in the absence of nitroglycerin. The effect of lesser concentrations of nitroglycerin was not assessed because sensitivity of the assay was limited and prohibitively large amounts of platelets would have been required. Protein-associated S-nitrosothiols were not measured in these experiments because only adducts to which the plasma membrane is permeable appear to be important for the effect of other organic nitrates noted in previous studies (27) .
Discussion
These experiments demonstrate that the reduced thiol, Nacetylcysteine, markedly potentiates inhibition of platelet aggregation by nitroglycerin and other organic nitrate vasodilators. N-Acetylcysteine was chosen for these experiments in place of other thiols because of its proved safety in humans and because of its demonstrated efficacy in potentiating the hypotensive effect of nitroglycerin in vivo (16) . In smooth muscle cells, the relaxing effect of nitroglycerin was felt initially to be mediated by a nitroglycerin "receptor" (30), through which specific tolerance could be induced by prolonged exposure to nitroglycerin and reversed by reduced thiols (15). Further studies by Ignarro's group (31) suggested that the effect of nitroglycerin on smooth muscle cells was more complex than this and that cGMP was an essential mediator of nitroglycerin-induced vasodilatation. In these experiments, increases in smooth muscle cGMP in response to incubation with nitroglycerin preceded decreases in vascular tone, supporting the importance of the cyclic nucleotide. In platelets, the inhibition of aggregation by nitroglycerin and other guanylate cyclase activators (nitroprusside, azide, and nitrite) suggests that cGMP is a crucial mediator of this inhibition (27) . The fact that the maximal increase in platelet cGMP preceded the maximal inhibition of aggregation further supports this hypothesis. Controversy (37) showed that cGMP either had no effect on platelet aggregation or else, at higher concentrations, inhibited aggregation. The data presented here show that, at least as far as inhibition of platelet aggregation by nitroglycerin is concerned, platelet cGMP levels maximally increase before maximal inhibition of aggregation, thereby arguing that elevation of cGMP is associated with inhibition of aggregation.
The ability of the reduced thiol, N-acetylcysteine, to potentiate the inhibitory effect of nitroglycerin further supports the importance of guanylate cyclase activity in the inhibition of platelet aggregation in these experiments. Preincubation with reduced thiol was essential for the expression of partially purified hepatic guanylate cyclase activity (38) . In addition, the fact that hepatic and pulmonary (38) guanylate cyclase are rapidly inactivated by molecular oxygen, sulfhydryl oxidants, and thiol alkylating agents suggests that the redox state of sulfhydryl groups on guanylate cyclase determines its activation.
Reduced thiols have also been found to stimulate activation of purified guanylate cyclase by nitroglycerin, among which are included cysteine, GSH, penicillamine, and dithiothreitol (26) .
In the metabolism of nitroglycerin, denitrification occurs in a process requiring that GSH be catalyzed in liver by an organic nitrate reductase (30); the specific enzyme that serves this function is probably a glutathione-S-transferase (39) . Denitrification is probably responsible not only for the metabolic fate of nitroglycerin, but also for its role as an activator of guanylate cyclase. Nitrite ion hydrolyzed from nitroglycerin reacts with reduced thiol to form S-nitroso-thiol compounds that, themselves, are very potent activators ofguanylate cyclase (26) , vasodilators (24) , and, as shown both in this study for Snitroso-N-acetylcysteine and in a recent study for other Snitroso-thiols (40), extremely potent inhibitors of platelet activation. The loss of GSH and the appearance of S-nitrosothiols in platelets incubated with nitroglycerin supports the existence of this mechanism in platelets. The chemical identity of the S-nitroso-thiol(s) that form intracellularly has yet to be determined, but the possible candidates include S-nitrosoglutathione, S-nitroso-cysteine, or, perhaps, S-nitroso-N-acetylcysteine itself.
What N-acetylcysteine does in this system is, as yet, not fully explained: it may serve as a source of thiol-reducing equivalents for the GSH system in the platelet; it may directly activate guanylate cyclase; it may serve as a reduced thiol source in the enzyme-catalyzed denitrification reaction; or it may serve as a substrate directly in the formation of S-nitrosothiols. Further studies are currently underway to clarify these issues.
In summary, the data presented here show the following: that (a) nitroglycerin and other organic nitrates inhibit platelet aggregation and that this inhibition is potentiated markedly by the reduced thiol, N-acetylcysteine; that (b) nitroglycerin, as other guanylate cyclase activators, inhibits platelet aggregation by inducing an increase in platelet cGMP levels that rise maximally before maximal inhibition of platelet aggregation; that (c) S-nitroso-thiols form when platelets are incubated with nitroglycerin; that (d) S-nitroso-N-acetylcysteine is an extremely potent inhibitor of platelet aggregation; and that (e) such Snitroso-thiols adducts are the active forms of nitroglycerin and other organic nitrates.
These data provide new insights into the possible effects of nitroglycerin on the vascular bed. At concentrations that are pharmacologically attainable in vivo, nitroglycerin reacts with GSH and/or other cellular thiols to form S-nitroso-thiols that not only vasodilate directly, but also markedly inhibit platelet aggregation. Inhibition of platelet activation and aggregation prevents synthesis of platelet-derived thromboxane A2, and thereby further potentiates local direct vasodilating effects. In light of these data, the use of S-nitroso-N-acetylcysteine or other S-nitroso-thiols as antihypertensive or antiplatelet agents deserves further study.
